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Abstract
Branched DNA (bDNA) is a signal amplification technology used in clinical and research laboratories to quantitatively detect
nucleic acids. An overnight incubation is a significant drawback of highly sensitive bDNA assays. The VERSANTH HIV-1 RNA
3.0 Assay (bDNA) (‘‘Versant Assay’’) currently used in clinical laboratories was modified to allow shorter target incubation,
enabling the viral load assay to be run in a single day. To dramatically reduce the target incubation from 16–18 h to 2.5 h,
composition of only the ‘‘Lysis Diluent’’ solution was modified. Nucleic acid probes in the assay were unchanged.
Performance of the modified assay (assay in development; not commercially available) was evaluated and compared to the
Versant Assay. Dilution series replicates (.950 results) were used to demonstrate that analytical sensitivity, linearity,
accuracy, and precision for the shorter modified assay are comparable to the Versant Assay. HIV RNA-positive clinical
specimens (n=135) showed no significant difference in quantification between the modified assay and the Versant Assay.
Equivalent relative quantification of samples of eight genotypes was demonstrated for the two assays. Elevated levels of
several potentially interfering endogenous substances had no effect on quantification or specificity of the modified assay.
The modified assay with drastically improved turnaround time demonstrates the viability of signal-amplifying technology,
such as bDNA, as an alternative to the PCR-based assays dominating viral load monitoring in clinical laboratories. Highly
sensitive bDNA assays with a single day turnaround may be ideal for laboratories with especially stringent cost,
contamination, or reliability requirements.
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Introduction
Branched DNA (bDNA) technology, first developed over twenty
years ago [1], is today widely used in clinical [2] and research [3]
laboratories to quantitatively detect specific nucleic acid sequenc-
es. bDNA quantitative hybridization technology has a wide
dynamic range and is sensitive enough for applications intended
to reliably detect very few target molecules [4]. The technology
has been described in detail elsewhere [4]. bDNA technology has
some advantages over PCR technology, commonly used for
applications requiring high sensitivity. Unlike PCR, where a
region of the intended target is exponentially amplified in order to
generate detectable signal, in bDNA assays only signal is amplified.
bDNA assays are consequently not susceptible to contamination
risks associated with PCR-based assays [5]. Minor sequence
variation in probe-binding regions of target will not compromise
assay performance, in contrast to PCR [6], leading to more robust
quantitation across genotypes [7]. Furthermore, reproducibility,
and therefore reliability, of bDNA assays is superior to PCR
assays, especially at the low end of an assay’s dynamic range [8].
However, a reduction in the processing time allowing the single
day turnaround now standard in clinical PCR assays, would
improve the productivity of laboratories utilizing bDNA. bDNA
is a hybridization technology in which a series of probes is
introduced to a sample well. Target is immobilized at the well
surface and an extended branching structure with many signal-
generating moieties is constructed to produce an amplified signal
[4]. The primary component of the run time is an overnight (16–
18 h) target incubation. Target incubation involves annealing of
unpurified lysed target nucleic acids to a set of probes used in
immobilizing the target and another set of probes to initiate
construction of the extended signaling structure. We have
modified the Versant HIV-1 RNA 3.0 Assay (bDNA) (‘‘Versant
Assay’’) currently in use in clinical laboratories to allow the viral
load assay to be run in a single day (assay in development; not
commercially available). An evaluation of the modified assay
consisting of analytical performance testing, a method compar-
ison with clinical specimens, a genotype equivalence study, and
testing of potentially interfering endogenous substances is
presented.
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In an initial experiment we simply shortened the standard 16–
18 h target incubation to a target period of 3 h, forcing the
otherwise unmodified Versant Assay to provide results in little over
a standard 8 h work shift. We examined analytical performance of
the unmodified shortened assay with a target dilution series of non-
infectious HIV-18E5/LAV virus (8E5) [9]. Performance suffered
when comparing analogous parameters previously reported [2] for
the Versant Assay. Assay sensitivity and precision were signifi-
cantly worse with a simple truncation of the target incubation
(Table S1).
Therefore, we focused on accelerating signal generation in the
assay by speeding the diffusion of the ,10 Kb target HIV RNA to
the well surface and accelerating hybridization of the assay probes
and target. Dilution series of target were analyzed to assess the
impact of assay modification in these evaluations. Diffusion is most
simply addressed by reducing the volume in the assay wells during
target incubation. However, there are at least two potential
problems with this approach. Surfaces of the wells have attached
capture probe oligonucleotides. When the assay solution volume is
reduced, some capacity for signal generation is inevitably lost as
the solution level falls below some of the capture oligonucleotides.
Additionally, sufficient solution must be present in the wells to
ensure that the small volume lost to evaporation during assay
manipulations does not significantly affect assay results.
Reducing the target incubation solution volume as low as 80 mL
still left sufficient solution in the wells such that evaporation was
not a problem under the assay conditions. Signal generation at
80 mL target incubation solution volume was much more rapid.
Salt and surfactant concentrations in the solution at the lower
volume were also adjusted to give rapid signal generation without
proportionally increasing background signal in negative samples.
Doubling these concentrations in the ‘‘Lysis Diluent’’ component
gave optimal results for the lower volume target incubation (Table
S2). Signal at 3 h with this modified, ‘‘low volume’’ condition was
virtually identical to signal at 15 h with the standard Lysis Diluent
volume across the quantitative range of the assay (Fig. 1).
Various polyanions were tested for ability to accelerate nucleic
acid hybridization [10] in the assay (Fig. 2). Several polyanions
that were examined significantly accelerated signal generation in
the assay. Among the polyanionic species in our experiments,
polyvinylsulfonic acid (PVSA) was consistently superior in rapidly
boosting assay signal across the quantitative range of the assay.
Optimization of PVSA concentration in the assay demonstrated
that 0.3% (w/v) PVSA in the Lysis Diluent significantly increased
signal generation, yet did not cause problems with precipitation
upon storage (data not shown). Finally, the lower volume Lysis
Diluent was prepared with PVSA (designated ‘‘M1 Lysis Diluent’’)
and used in assays with low volume target incubation, demon-
strating that the two modifications together had some cumulative
benefit in rapid signal generation (Fig. 3).
Preliminary experiments indicated that the levels of signal
generated in the Versant Assay could be reached in as little as
2.5 h target incubation time simply by using M1 Lysis Diluent in
the assay. Probe-containing components and associated volumes of
addition were not changed. Assay evaluations with the M1 Lysis
Diluent and assay software modified to accommodate 2.5 h target
incubation (the ‘‘modified assay’’) were performed, including
analytical performance testing, a method comparison with clinical
Figure 1. Signal generation in standard and low volume assays. The standard assay was run with 3 and 15 h target incubation (140 mL) and
the low volume assay was run with 3 h target incubation (80 mL). Identical lots of all components except Lysis Diluent were used on a single
instrument for the three conditions. A dilution series of 8E5 in Seracon II at three concentrations (n=10 for each condition) generated nearly identical
average Relative Light Units (RLUs) for standard volume target incubation at 15 h and low volume target incubation volume at 3 h. Signal in negative
samples remained unchanged (n=6 for each condition).
doi:10.1371/journal.pone.0033295.g001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33295Figure 2. Polyanions in target incubation solution. In this example, addition of 1% (w/V) of polyacrylic acid (PAA), polyantholesulfuric acid
(PASA), or polyvinylsulfonic acid (PVSA) to the Lysis Diluent (LD, control) caused different enhancement of signal generation relative to the control
condition. An 8E5 sample at 80,000 copies/mL (n=5 for each condition) was analyzed here on a single plate with 3 h target incubation. Superior
signal enhancement by PVSA relative to alternative polyanions was observed throughout our experiments. No polyanion caused discernable increase
in signal with negative samples (n=1 for each condition).
doi:10.1371/journal.pone.0033295.g002
Figure 3. Cumulative effect of lower volume and PVSA addition. Three conditions were compared in this experiment: Versant HIV-1 RNA 3.0
Assay with standard volume target incubation (140 mL), low volume target incubation (80 mL), or low volume target incubation plus PVSA (80 mL,
PVSA). Two concentrations of 8E5 (n=4 for each level of each condition) were analyzed on a single plate with 2 h target incubation. Enhanced signal
generation (RLU average) was observed for low volume target incubation, and further improvement was observed upon addition of PVSA to the low
volume target incubation. Although signal increased slightly for negative samples (n=6 for each condition) in the low volume conditions, signal for
the low concentration positive samples in the low volume conditions increased more than enough to compensate.
doi:10.1371/journal.pone.0033295.g003
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interfering endogenous substances.
Using data gathered from 450 total individually collected HIV
RNA-negative plasma specimens across eighteen runs with three
kit/M1 Lysis Diluent lot combinations, a detection cutoff of 29
copies/mL was defined to deliver specificity with a lower level of
the 95% confidence interval of at least 95% (Table 1, Negative
cutoff determination). Specificity with the defined detection cutoff
was verified as .95% by 144 additional individual HIV-negative
plasma specimens across twelve more runs with the remaining
three kit/M1 Lysis Diluent lot combinations (Table 1, Negative
cutoff verification). The verified detection cutoff was then used in
analyzing all other experiments.
Wells across all thirty runs containing dilution series replicates
were used to determine analytical sensitivity, linearity, accuracy,
and precision for the modified assay. The assay detection cutoff
ascertained from the individual negative specimens was used in
determining the assay limit of detection (LoD, 95% detection rate)
as 70 copies/mL (95% CI from 64 to 76 copies/mL) by logistic
curve fit. Linearity of the modified assay was evaluated by
determining the absolute deviation of geometric mean quantita-
tions from the predicted values on the linear regression line for
dilution series levels above the LoD. These mean differences for all
levels of the dilution series above the LoD were #0.07 log10
(Table 2, Log Difference). Accuracy of the modified assay was
determined from the difference in measured and expected mean
quantitations for dilution series levels. These differences were
#0.06 log10 for all levels above the assay LoD with the modified
assay (Table 2, Log Recovery). The range of total percent
coefficients of variation (%CVs) corresponding to dilution series
levels above the LoD in the modified assay were 13.8–31.4% for
the modified assay (Table 2). Analytical sensitivity, linearity,
accuracy, and precision determined with the modified assay are
comparable to the analogous parameters previously reported [2]
for the Versant Assay.
Quantitative equivalence of the modified assay and the Versant
Assay was established with a set of common clinical specimens
quantified in both assays (Fig. 4). Results quantifying below the LoD
ofthemodifiedassay(6results)wereexcludedfromanalysis.Average
log difference between the Versant and modified assays was 20.025
(95% CI from 20.067 to 0.018), indicating no statistically significant
difference in quantification between the two assays. Deming
regression showed linearity for a plot of log quantifications for the
Versant Assay against the log quantifications of the modified assay
acrossthe rangeexamined (slope=0.974 with 95%CIfrom 0.913 to
1.04). A Bland-Altman plot (Fig. 5) demonstrated no evidence of
proportional bias across the linear range of the assay (regression
slope=20.026; 95% CI from 20.086 to 0.035).
Genotype equivalence was demonstrated with a high concentration
series (,50,000 copies/mL) and a low concentration series (,500
copies/mL) of HIV subtype samples. The modified assay and the
Versant Assay quantified each sample very similarly (Figs. S1 and S2).
Like the Versant Assay [2], none of the endogenous substances
tested for potential interference in the modified assay had a
significant effect on assay specificity with HIV-negative samples or
quantification of target at approximately 1,000 copies/mL in
Seracon II (Table S3).
Discussion
The modified bDNA assay demonstrated performance charac-
teristics comparable to the more time-consuming Versant HIV-1
RNA 3.0 Assay (bDNA). The dramatically shortened target
incubation was enabled by modification of only the Lysis Diluent
used in target incubation. The assay retains advantages of bDNA
technology, including superior reproducibility, reliability, and
insusceptibility to contamination. Throughput with the modified
assay is comparable to analogous PCR-based assays used in
clinical laboratories. A single Versant 440 Molecular System can
run two 96 well plates simultaneously, allowing the modified HIV-
1 assay to routinely process 192 tests per day. bDNA assays with a
single day turnaround may be ideal for laboratories with especially
stringent cost, contamination, or reliability requirements.
Similar shortened target incubation can be implemented in bDNA
assays targeting a variety of clinically relevant nucleic acid analytes.
The HIV analyte targeted in the viral load assay presented here has a
relatively stringent sensitivity requirement. The target incubation
time of a bDNA assay can most likely be further shortened when
targeting analytes lacking acute sensitivity requirements.
Materials and Methods
Assay Kits and Systems
The modified assay used Versant Assay kits, removing the
original Lysis Diluent component and replacing it with M1 Lysis
Diluent. All other Versant Assay reagents were used unchanged.
Assays were performed on the VERSANTH 440 Molecular
System with software modified to allow a target incubation period
of 2.5 h. Some preliminary experimentation used in developing
the M1 Lysis Diluent formulation was performed on the older
System 340 bDNA Analyzer. Unmodified kit calibrators and
controls from the Versant Assay were used in the modified assay to
generate a standard curve and verify plate validity.
Reagent Modification
In M1 Lysis Diluent, salt and surfactant concentrations were
doubled relative to the Lysis Diluent in the Versant Assay.
Concentrations of the remaining components of the Lysis Diluent
were identical in M1 Lysis Diluent. Additionally, polyvinylsulfonic
acid was added to M1 Lysis Diluent (0.3% (w/v)). The target
incubation solution volume in the modified assay was reduced to
80 mL from 140 mL per well in the Versant Assay, by adding
60 mL, instead of 120 mL, of ‘‘Lysis Working Reagent’’ made from
M1 Lysis Diluent (Table S2).
Table 1. Specificity with individual HIV-negative clinical specimens: determination of 29 copies/mL as the negative cutoff and
subsequent verification in the modified assay.
Negative cutoff determination Negative cutoff verification
N N below negative cutoff
Specificity (95% Lower
Confidence Limit) N N below negative cutoff
Specificity (95% Lower
Confidence Limit)
450 436 96.9% (95.2%) 144 140 97.2% (93.8%)
doi:10.1371/journal.pone.0033295.t001
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Analytical sensitivity, specificity, linearity, accuracy and preci-
sion were evaluated by testing three M1 Lysis Diluent lots made
from diverse raw materials in all six permutations available with
two assay kit lots. Specificity testing was performed on individual
HIV-negative plasma specimens (ProMedDx). A dilution series of
non-infectious HIV-18E5/LAV virus (8E5) [9] in Seracon II
(SeraCare) was gravimetrically prepared. The 8E5 stock was
previously value assigned from a reference transcript quantified by
phosphate analysis [11]. The dilutions were then value assigned in
the Versant Assay. This is identical to the dilution series
preparation in a published evaluation of the Versant Assay [2],
except 8E5 was substituted for b-propiolactone-treated virus. The
dilution series was used for all analytical performance testing.
Table 2. Analytical performance summary for the modified HIV-1 bDNA assay.
Level (copies/mL) Total N Positive N Log Recovery Log Difference Total %CV
584926 197 197 0.06 0.06 16.6
58493 197 197 0.01 0.01 20.3
5849 199 199 0.06 0.07 13.8
585 196 196 0.01 0.01 31.3
117 347 345 20.05 20.04 30.4
88 347 341 20.06 20.05 31.4
58 348 313 20.04 20.03 29.7
doi:10.1371/journal.pone.0033295.t002
Figure 4. Method comparison of the modified bDNA assay and the VERSANT HIV-1 bDNA 3.0 Assay. Log quantitations of 135 HIV-
positive clinical specimens with the modified assay were measured and plotted. The Deming regression line (slope=0.974 with 95% CI from 0.913 to
1.04) is indicated in the plot.
doi:10.1371/journal.pone.0033295.g004
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Studentized residuals .4 for relative light unit signal were
considered outliers and excluded from analysis (5 of 970 results).
Method Comparison
In the method comparison experiment, aliquots from 141 HIV-
positive clinical specimens (ProMedDx, Bio Collections, or
Northwest Biomedical) with viral loads distributed across the
assay range were quantified in the Versant Assay and the modified
assay. These specimens were collected with written informed
consent of the participants and following protocols approved by
New England IRB (ProMedDx), Independent Investigational
Review Board, Inc. (BioCollections), or Beijing Youan Hospital
IRB (Northwest Biomedical). The specimens were purchased
delinked and deidentified from the participants by the commercial
sources. An unweighted Deming regression was used in the
method comparison analysis [12]. No outlier analysis was
performed on the method comparison data.
Genotype Equivalence and Potentially Interfering
Endogenous Substances
A panel of HIV RNA-positive samples composed of eight HIV-1
subtypes (SeraCare) was used to examine genotype quantification
equivalence. Two levels of each panel member (,50,000 and ,500
copies/mL) were prepared by gravimetric dilution in Seracon II.
Elevated levels of several endogenous substances, including hemo-
globin (200 mg/dL), triglycerides (2000 mg/dL), albumin (6 g/dL),
c-globulins (6 g/dL), and bilirubin (20 mg/dL), were tested for
potential interference in the modified assay. These levels are derived
from recommended test levels in CLSI document EP7-A2 [13]. The
endogenous substance samples were prepared in Seracon II, with
8E5 gravimetrically spiked to create HIV-positive samples.
Supporting Information
Figure S1 Eight HIV subtypes at ,50,000 copies/mL
quantified by the modified assay and the VERSANT
HIV-1 bDNA 3.0 Assay. Quantification by the VERSANT
HIV-1bDNA 3.0 Assay (32 replicates of each subtype across 4
plates) is very similar to quantification by the modified assay (5
replicates of each subtype on a single plate).
(TIF)
Figure S2 Eight HIV subtypes at ,500 copies/mL
quantified by the modified assay and the VERSANT
HIV-1bDNA 3.0 Assay. Quantification by the VERSANT
HIV-1 bDNA 3.0 Assay (32 replicates of each subtype across 4
Figure 5. Bland-Altman plot of method comparison data between the modified bDNA assay and the VERSANT HIV-1 bDNA 3.0
Assay. No evidence of proportional bias across the linear range of the assay is apparent (regression slope=20.026; 95% CI from 20.086 to 0.035).
doi:10.1371/journal.pone.0033295.g005
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replicates of each subtype on a single plate).
(TIF)
Table S1 Analytical performance summary for the
unmodified HIV-1 bDNA assay with truncated target
incubation.
(DOC)
Table S2 HIV Target Incubation: VERSANT versus
modified assay volumes. In the Versant Assay, all reagents
(except M1 Lysis Diluent) in Table S3 are supplied in separate
vials. The components are combined following the instructions for
use provided with the Versant Assay to make a ‘‘Lysis Working
Reagent’’, which is added (120 mL) to each sample well (total
incubation volume 140 mL). In the modified assay, M1 Lysis
Diluent (45 mL) is substituted for Lysis Diluent and the resulting
Lysis Working Reagent is added (60 mL) to each sample well (total
incubation volume 80 mL).
(DOC)
Table S3 Endogenous substances: specificity with HIV-
negative samples and quantification with HIV-positive
samples in the modified assay.
(DOC)
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